摘要:
Objective:Using the expression profile microarray to obtain the differentially expressed genes (DEGs) inside population(SP) and non-SP (NSP) of osteosarcoma (OS) MG63 cells,to discover the potential therapeutic targets for OS.Methods:To isolate SP and NSP from the MG63 cells human OS cell line using fluorescence-activated cell sorter.Expression profile microarray was used to detect the DEGs in SP and NSP of MG63 cells,2.0-fold changes in gene expression was set as the preliminary screening criteria.The enrichment of functions and signaling pathways were conducted by the Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes(KEGG).Five selected DEGs were verified by real-time fluorescent quantitative polymerase chain reaction(qRT-PCR).Results:A total of 7,332 genes were screened as DEGs,of which 3,661 genes were upregulated and 3,671 genes were downregulated in SP vs.NSP of MG63 cells.GO enrichment analysis revealed that the DEGs were mainly involved in signal transduction,cell adhesion,response,membrane and binding.KEGG pathway analysis showed that the genes were primarily enriched in hematopoietic cell lineage,transcriptional misregulation in cancer,cancer,regulation of actin cytoskeleton,cytokine-cytokine receptor interaction and cGMP-PKG signaling pathway,etc.Conclusion:The studies provide an overview of the gene expression profile between SP and NSP of MG63 cells.Analysis of the GO enrichment and KGEE pathway function of DEGs implied that KLK5,CCNA1,TFPI2 and RAPH1 might be the therapeutic targets for cancer stem cells(CSCs) of OS.%目的:使用表达谱芯片获得骨肉瘤MG63侧群细胞(SP)和非SP(NSP)中的差异表达基因,从中挖掘骨肉瘤的潜在治疗靶基因.方法:使用流式分选仪从人骨肉瘤细胞系MG63细胞中分离出SP和非SP,并使用表达谱芯片技术检测MG63细胞SP和NSP中的差异表达基因,以2倍的差异表达倍数变化设定为初步筛选基因的标准.利用基因本体论(GO)、京都百科全书基因和基因组(KEGG)途径进行功能和信号通路富集.分别从SP中过表达和低表达的差异基因中选择5个,采用荧光定量PCR法(RT-qPCR)对其进行表达情况的验证.结果:在MG63细胞中,SP和NSP,共有7 332个基因被筛选为差异表达基因,其中3 661个基因被上调,3 671个基因被下调.GO富集分析显示,差异表达的基因主要参与信号转导、细胞粘附、反应、膜和结合.KEGG通路分析显示,这些基因主要富集于造血细胞谱系,癌症中的转录失调,癌症,肌动蛋白细胞骨架的调节,细胞因子—细胞因子受体相互作用和cGMP-PKG信号通路等.结论:这些研究提供了MG63细胞中SP和NSP之间差异基因表达谱的概述,并使用GO和KEGG通路对其差异表达基因进行功能富集,提示了KLK5,CCNA1,TFPI2和RAPH1可能是骨肉瘤CSCs治疗的靶点.